ProfileGDS5678 / 1416680_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 98% 98% 98% 98% 97% 98% 97% 98% 97% 97% 98% 98% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.8546698
GSM967853U87-EV human glioblastoma xenograft - Control 29.9430598
GSM967854U87-EV human glioblastoma xenograft - Control 39.9960298
GSM967855U87-EV human glioblastoma xenograft - Control 49.9170798
GSM967856U87-EV human glioblastoma xenograft - Control 59.6408797
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.7917198
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.4157397
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.6323798
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.357797
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.5427597
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.6429998
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.8863698
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.6552597
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.5760397